MDMB-FUBICA, an indole-based synthetic cannabinoid, is thought to exhibit strong agonistic activity on the CB1 receptor and has gained notoriety as a designer drug available for online purchase.

The EMCDDA first identified MDMB-FUBICA in Sweden in February 2015. This synthetic compound is commonly marketed in e-liquid form, intended for use in electronic cigarettes.

showIUPAC name
CAS Number1971007-91-6 
PubChem CID129522107
Chemical and physical data
Molar mass396.462 g·mol−1

Side effects

MDMB-FUBICA’s indazole counterpart, MDMB-FUBINACA, has been associated with over 1000 hospitalizations and 40 fatalities due to intoxication by March 2015.


Regarding its legal status, MDMB-FUBICA is prohibited in Sweden.


1. What is MDMB-FUBICA?

MDMB-FUBICA is a synthetic cannabinoid, and it belongs to the indole-based class of designer drugs. It’s presumed to be a potent agonist of the CB1 receptor.

2. What is the relationship between MDMB-FUBICA and MDMB-FUBINACA?

MDMB-FUBINACA is an indazole analogue of MDMB-FUBICA. While they share structural similarities, MDMB-FUBINACA has been linked to a significant number of hospitalizations and deaths due to intoxication.

3. What are the potential risks associated with MDMB-FUBICA use?

Like other synthetic cannabinoids, the use of MDMB-FUBICA carries inherent risks, including severe adverse effects and, in some cases, fatalities. It is essential to be aware of these dangers.

4. Is MDMB-FUBICA legal in any country?

MDMB-FUBICA’s legal status varies from one country to another. It is crucial to check the laws and regulations in your specific region, but it is banned in Sweden.

5. How is MDMB-FUBICA typically consumed?

MDMB-FUBICA is often found in e-liquid form, meant for use in electronic cigarettes (e-cigarettes). Users may also attempt to inhale or vaporize it.

6. Can you provide more information about its discovery in Sweden?

MDMB-FUBICA’s presence in Sweden was first detected in February 2015. It subsequently gained attention due to the reported health issues associated with its use.

7. What precautions should I take when it comes to MDMB-FUBICA?

The best precaution is to avoid using MDMB-FUBICA entirely, given the significant risks it poses. If you encounter adverse effects or suspect someone has been exposed, seek immediate medical attention.

8. Where can I find more information about MDMB-FUBICA?

You can find further information through reliable sources such as government health agencies, research publications, and educational resources dedicated to substance abuse prevention and awareness. Staying informed is essential to understand the potential dangers of this synthetic cannabinoid.


  1. In a comprehensive study by Wagmann and colleagues (July 2022), the toxicokinetics of synthetic cannabinoids were explored in-depth, shedding light on the in vitro contributions of human carboxylesterases. This research was published in the Archives of Toxicology.
  2. The “Hamarosan: 2015. Évi Európai Kábítószer – Jelentés” (PDF) by the Hungarian National Focal Point (NFP) offers insights into the European Drug Report of 2015, providing valuable information on the landscape of substances like MDMB-FUBICA. This document was retrieved in June 2015.
  3. A study by Peace and colleagues (February 2017) identified MDMB-FUBINACA in commercially available e-liquid formulations designed for use in electronic cigarettes. The findings were documented in Forensic Science International.
  4. The Federal Drug Control Service of the Russian Federation reported on “Очередная жертва спайса” (Another Spice Fatality) on 17th March 2015. This report, highlighting the impact of synthetic cannabinoids like MDMB-FUBICA, was archived from the original on 14th July 2015.
  5. Folkhälsomyndigheten, on 1st June 2015, released information on “23 nya ämnen kan klassas som narkotika eller hälsofarlig vara” (23 New Substances Proposed for Classification as Narcotics or Hazardous Materials). This announcement sheds light on the evolving landscape of controlled substances and was retrieved on 24th July 2015.

Leave a Comment

Your email address will not be published. Required fields are marked *